You have 9 free searches left this month | for more free features.

Ofatumumab

Showing 1 - 25 of 163

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Ofatumumab in Portuguese Multiple Sclerosis Patients

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 30, 2023

Quality of Life of Multiple Sclerosis Patients Treated With

Not yet recruiting
  • Multiple Sclerosis (MS)
  • ofatumumab
  • (no location specified)
Nov 27, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Tampa (High Dose Methylprednisolone (HDMP), Ofatumumab,

Active, not recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • High Dose Methylprednisolone (HDMP)
  • +2 more
  • Tampa, Florida
    H. Lee Moffitt Cancer Center and Research Institute
Jan 12, 2023

Early Versus Late Ofatumumab Use in Austrian RMS-Patients Over 2

Not yet recruiting
  • Relapsing Multiple Sclerosis
  • Ofatumumab
  • (no location specified)
Mar 17, 2023

CLL, SLL Trial in Boston (Ofatumumab, High-Dose Methylprednisolone, Alemtuzumab)

Terminated
  • CLL
  • SLL
  • Ofatumumab
  • +2 more
  • Boston, Massachusetts
  • +1 more
Jan 30, 2023

Kesimpta (Ofatumumab) Pregnancy Registry

Recruiting
  • Multiple Sclerosis
  • Pregnancy
  • Kesimpta
  • La Jolla, California
    Novartis Investigative Site
Jan 16, 2023

Leukemia, Lymphoma Trial in Houston (Ofatumumab)

Active, not recruiting
  • Leukemia
  • Lymphoma
  • Ofatumumab
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Dec 9, 2022

Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia) Trial run by the National Heart, Lung, and Blood Institute

Active, not recruiting
  • Small Lymphocytic Lymphoma
  • CLL (Chronic Lymphocytic Leukemia)
  • Fludarabine Phosphate
  • +2 more
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Oct 13, 2022

Multiple Sclerosis COVID-19/Vaccination Treated With Ofatumumab

Completed
  • Multiple Sclerosis
    • East Hanover, New Jersey
      Novartis
    Jul 14, 2023

    Ocrelizumab and Ofatumumab Administration in Relapsing Multiple

    Completed
    • Relapsing Forms of Multiple Sclerosis
    • Lutherville, Maryland
    • +1 more
    Oct 19, 2022

    Multiple Sclerosis Trial in Germany (Ofatumumab)

    Active, not recruiting
    • Multiple Sclerosis
    • Ofatumumab
    • Berlin, Germany
    • +5 more
    Jan 13, 2023

    Neuromyelitis Optica Spectrum Disorder Trial in Xi'an (Ofatumumab)

    Recruiting
    • Neuromyelitis Optica Spectrum Disorder
    • Ofatumumab
    • Xi'an, Shaanxi, China
      Tangdu Hospital
    Aug 16, 2022

    Chronic GVHD Trial in United States (Ofatumumab)

    Completed
    • Chronic Graft Versus Host Disease
    • Ofatumumab
    • Phoenix, Arizona
    • +3 more
    Sep 30, 2022

    Early Patients Initiating Ofatumumab for Treatment of Multiple

    Completed
    • Multiple Sclerosis
    • Ofatunumab
    • East Hanover, New Jersey
      Novartis Investigative Site
    Nov 7, 2022

    Immune Cells and Meningeal Lymphatic Drainage in Demyelinating

    Recruiting
    • Multiple Sclerosis
    • +2 more
    • Ofatumumab
    • Tianjin, Tianjin, China
      Tianjin Medical University General Hospital
    Oct 19, 2022

    RMS Patients on Ofatumumab or Ocrelizumab inReal-World Setting

    Recruiting
    • Relapsing Multiple Sclerosis
    • Ofatumumab
    • Ocrelizumab
    • Dubai, United Arab Emirates
      Novartis Investigative Site
    Aug 8, 2022

    COVID-19 Vaccine in Multiple Sclerosis Participants Treated With

    Completed
    • Relapsing Multiple Sclerosis
    • Ofatumumab
    • Covid-19 vaccine
    • Phoenix, Arizona
    • +4 more
    Jan 23, 2023

    Kesimpta® in Swiss Multiple Sclerosis Patients -Observational

    Recruiting
    • Multiple Sclerosis
    • Ofatumumab
    • Baden, Aargau, Switzerland
    • +17 more
    Jan 20, 2023

    Relapsing Multiple Sclerosis (RMS) Trial in United States (Ofatumumab, mRNA COVID-19 vaccine, interferon or glatiramer acetate)

    Recruiting
    • Relapsing Multiple Sclerosis (RMS)
    • Ofatumumab
    • +2 more
    • Phoenix, Arizona
    • +3 more
    Jul 20, 2022

    Non-Hodgkin's Lymphoma Trial in Philadelphia (drug, procedure, genetic)

    Completed
    • Non-Hodgkin's Lymphoma
    • Philadelphia, Pennsylvania
      Sidney Kimmel Cancer Center at Thomas Jefferson University
    Sep 14, 2022

    WOE of Anti-CD20 Therapies

    Not yet recruiting
    • Multiple Sclerosis
    • (no location specified)
    Oct 31, 2023

    Kesimpta Pregnancy and Infant Safety Study Using Real World Data

    Not yet recruiting
    • Multiple Sclerosis
    • Multiple sclerosis disease modifying drug
    • (no location specified)
    Nov 27, 2023

    From Patient and Care Partner on Injection and Device for

    Recruiting
    • Multiple Sclerosis
    • Kesimpta
    • East Hanover, New Jersey
      Novartis Investigative Site
    Jan 31, 2023

    Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab

    Recruiting
    • Relapsing Remitting Multiple Sclerosis
    • Ofatumumab
    • Los Angeles, California
      University of Southern California
    Feb 3, 2022

    Relapse Remitting Multiple Sclerosis Trial in United States (Ofatumumab)

    Recruiting
    • Relapse Remitting Multiple Sclerosis
    • Ofatumumab
    • Chandler, Arizona
    • +16 more
    Jan 13, 2023